




International conference on immunotherapy-radiotherapy combinations

September 22-23-24 2016

GUSTAVE / ROUSSY
CANCER CAMPUS
GRAND PARIS





Thursday 22 :

9.30-10.00 Opening

- Welcome and introduction : Pr Alexander Eggermont, director of Gustave Roussy cancer campus
- Welcome on behalf EORTC : Pr Vincent Grégoire, vice president of EORTC.

10.00-12.00 The basis of immune-oncology applied to radiotherapy

- Immune cell death , consequences for radiotherapy, Dr Aurélien Marabelle, Gustave Roussy.
- Cell death mechanisms after IR and immune response : Dr Jean-Luc Perfettini, INSERM, Gustave Roussy
- Induction of neoantigen by irradiation : Pr Tom Schumacher, the NKI, Amsterdam

11.45-12.30

- Microbiota : an new player in I/O? Pr Laurence Zitvogel, Gustave Roussy Villejuif
- Priming versus amplification after irradiation? Dr Lisa Coussens, U of Oregon Portland USA.

12.30-14.00 Lunch

14.00-15.30

15.30-16.00 Coffee Break

16.00-18.45 Targeting the checkpoints

- Targeting CTLA4 : Pr S Demaria, NY USA
- Defining the optimal drug-RT interval :Pr T Illidge, Manchester UK.
- Development of I/O in melanoma : lessons learned. Pr Caroline Robert, Gustave Roussy.
- The abscopal effect in the clinic from theory to observation : Pr Formenti, NY USA

Friday 23

8.30-10.00 Biomarkers

- Immune contexture of radiation response : Dr Jerome Galon, INSERM PARIS V
- The imaging of inflammation. Dr Charles Ferte, Gustave Roussy

10.00-10.30 Coffe break

10.30-12.00 Macrophages and response to radiotherapy

- vascular response, impact on macrophages after IR Beckove, Regensburg
- Activation of NFKB and response of macrophages. Maria José Oliveira, Porto, Portugal
- response of macrophages to IR : Gailp US, Erlangen-Nurnenberg, DE

12.00-30 Keynote lecture

- Inteplay between CD8 cells and high dose radiotherapy :
Pr R Wechselbaum, U. of Chicago USA

12.30-14.00 Lunch break and exhibition

14-15.30 Views and controversies regarding I/O in radiotherapy

- Immuno oncology revolutionizes drug development, Pr Jean-Charles Soria, Villejuif

- The challenges from a radiation oncologist's perspective : Prof Marcel Verheij, the NKI, Amsterdam
- The challenges from a medical oncologist's perspective : Prof J Taberner, Barcelona, Spain

15.30-16.00

- Combining a vaccine for radiosensitization of HPV related tumors, Pr Eric Tartour, HEGP AHHP Paris
- The induction of an "immune hub" through irradiation, C-Vanpouille box, NYU, USA
- Development radiotherapy and immune oncology trials : the experience of an academic radonc inside big pharma.
- Pr David Raben, U of Colorado, USA
- Dr Ataman Ozlem, Eisai, NY USA

16.00-18.00

- Amplifying the immune signal with IL-2, Prof Philippe Lambin, Maastricht NL
- I/O trials ongoing at the Royal Marsden, London, UK.
- The link between DNA repair and I/O :

19.45 Gala dinner

Saturday 24

9.00-10.30

- Immuno oncology trials in radiation therapy :
- Novel Biological end-points needed? Pr Ignacio Mellero, Navarre Spain
- Novel statistical design ? Dr Emilie Lanoy Gustave Roussy

10.30-11.00 Coffee break

11.00-12.30

- I/O trial viewed from the EORTC lung tumor group, Pr Benjamin Besse, Villejuif
- What AE may we expect : Dr Christophe Massard, Villejuif

- Immuno oncology trials from the EORTC ROG group
- NRJ trials : Pr Bo Lu, Jefferson, Philadelphia USA
- Oligometastatic trials : Pr Eric Deutsch, Villejuif

12.30 Farewell